Jardiance®

Active substance empagliflozin
Holder Boehringer Ingelheim International GmbH
Status Running
Indication treatment of adult patients with heart failure with preserved ejection fraction (ejection fraction >40%)
Public documents Approbation
  Information for the patient
  Informed consent
Last update

07/03/2022

 

Last updated on 27/06/2022